Notice: This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrends XTLB vs. VYNE, RAPT, BRNS, HILS, LTRN, BLRX, VRCA, CLNN, RVPH, and LUMOShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include VYNE Therapeutics (VYNE), RAPT Therapeutics (RAPT), Barinthus Biotherapeutics (BRNS), Hillstream BioPharma (HILS), Lantern Pharma (LTRN), BioLineRx (BLRX), Verrica Pharmaceuticals (VRCA), Clene (CLNN), Reviva Pharmaceuticals (RVPH), and Lumos Pharma (LUMO). These companies are all part of the "pharmaceutical preparations" industry. XTL Biopharmaceuticals vs. VYNE Therapeutics RAPT Therapeutics Barinthus Biotherapeutics Hillstream BioPharma Lantern Pharma BioLineRx Verrica Pharmaceuticals Clene Reviva Pharmaceuticals Lumos Pharma XTL Biopharmaceuticals (NASDAQ:XTLB) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Does the MarketBeat Community believe in XTLB or VYNE? XTL Biopharmaceuticals received 50 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. Likewise, 71.82% of users gave XTL Biopharmaceuticals an outperform vote while only 63.04% of users gave VYNE Therapeutics an outperform vote. CompanyUnderperformOutperformXTL BiopharmaceuticalsOutperform Votes7971.82% Underperform Votes3128.18% VYNE TherapeuticsOutperform Votes2963.04% Underperform Votes1736.96% Is XTLB or VYNE more profitable? XTL Biopharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,896.55%. XTL Biopharmaceuticals' return on equity of 0.00% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets XTL BiopharmaceuticalsN/A N/A N/A VYNE Therapeutics -6,896.55%-43.73%-38.55% Do analysts prefer XTLB or VYNE? VYNE Therapeutics has a consensus target price of $5.75, suggesting a potential upside of 112.96%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe VYNE Therapeutics is more favorable than XTL Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00VYNE Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to XTLB or VYNE? In the previous week, VYNE Therapeutics had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for VYNE Therapeutics and 2 mentions for XTL Biopharmaceuticals. VYNE Therapeutics' average media sentiment score of 0.17 beat XTL Biopharmaceuticals' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment XTL Biopharmaceuticals Neutral VYNE Therapeutics Neutral Which has more volatility and risk, XTLB or VYNE? XTL Biopharmaceuticals has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Do institutionals & insiders hold more shares of XTLB or VYNE? 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 1.8% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has higher valuation and earnings, XTLB or VYNE? XTL Biopharmaceuticals has higher earnings, but lower revenue than VYNE Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXTL BiopharmaceuticalsN/AN/A-$1.78MN/AN/AVYNE Therapeutics$420K94.82-$28.45M-$0.86-3.14 SummaryVYNE Therapeutics beats XTL Biopharmaceuticals on 8 of the 15 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.08M$6.39B$5.06B$8.66BDividend YieldN/A8.04%5.09%4.06%P/E RatioN/A10.80101.8517.37Price / SalesN/A245.131,196.8169.07Price / CashN/A53.4940.9136.36Price / Book4.519.306.335.87Net Income-$1.78M$154.14M$119.64M$225.66M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL Biopharmaceuticals0.0648 of 5 stars$1.85+1.6%N/A+88.8%$10.08MN/A0.00N/AUpcoming EarningsShort Interest ↑VYNEVYNE Therapeutics2.6118 of 5 stars$2.70-4.9%$5.75+113.0%-32.2%$39.83M$420,000.00-3.1430Short Interest ↑RAPTRAPT Therapeutics4.5971 of 5 stars$1.11-14.0%$9.50+759.7%-91.6%$38.63M$1.53M-0.4080Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBRNSBarinthus Biotherapeutics2.3244 of 5 stars$0.97-29.7%$5.83+501.3%-67.1%$38.36M$800,000.00-0.65107Short Interest ↑News CoverageGap DownHigh Trading VolumeHILSHillstream BioPharmaN/A$2.17-2.7%N/A+1,045.7%$38.20MN/A-3.011Gap DownLTRNLantern Pharma0.8766 of 5 stars$3.54+1.4%N/A-8.1%$38.18MN/A-1.9920Analyst RevisionBLRXBioLineRx2.0891 of 5 stars$0.48+4.4%$21.00+4,315.9%-74.4%$38.02M$4.80M-1.0640Upcoming EarningsAnalyst ForecastShort Interest ↑News CoverageGap UpVRCAVerrica Pharmaceuticals4.6604 of 5 stars$0.83-3.5%$9.60+1,051.8%-76.0%$38.01M$5.12M-0.4640CLNNClene3.1967 of 5 stars$4.53-3.4%$71.33+1,474.7%-50.8%$37.87M$650,000.00-0.86100Upcoming EarningsAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageRVPHReviva Pharmaceuticals3.0623 of 5 stars$1.13-6.6%$15.50+1,277.8%-75.4%$37.62MN/A-1.015News CoverageLUMOLumos Pharma3.1612 of 5 stars$4.33flat$8.63+99.2%+44.3%$37.45M$2.05M-1.0130Short Interest ↓ Related Companies and Tools Related Companies VYNE Therapeutics Competitors RAPT Therapeutics Competitors Barinthus Biotherapeutics Competitors Hillstream BioPharma Competitors Lantern Pharma Competitors BioLineRx Competitors Verrica Pharmaceuticals Competitors Clene Competitors Reviva Pharmaceuticals Competitors Lumos Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XTLB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XTLB Stock Alerts